<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00174642</url>
  </required_header>
  <id_info>
    <org_study_id>HMR1964A_3506</org_study_id>
    <secondary_id>EUDRACT # : 2004-002036-25</secondary_id>
    <nct_id>NCT00174642</nct_id>
  </id_info>
  <brief_title>Opposing Step-by-step Insulin Reinforcement to Intensified Strategy</brief_title>
  <acronym>OSIRIS</acronym>
  <official_title>Comparison of Three Therapeutic Strategies for Treating Type 2 Diabetes Mellitus Patients Poorly Controlled With Basal Insulin Associated With Oral Antidiabetic Drugs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary objectives :

        -  To show the non inferiority in terms of efficacy (HbA1c) of insulin glargine plus
           metformin combined with 1 to 3 bolus of insulin glulisine introduced progressively (Arm
           2) compared with insulin glargine plus metformin combined with 3 bolus of insulin
           glulisine (Arm 1), in type 2 diabetes mellitus patients poorly controlled on basal
           insulin therapy with oral antidiabetic drugs.

        -  To show the non inferiority in terms of efficacy (HbA1c) of insulin glargine plus
           metformin combined with 1 to 3 bolus of insulin glulisine introduced progressively (Arm
           2) compared with insulin glargine plus metformin and insulin secretagogue (sulfonylurea
           or glinide) combined with 1 to 3 bolus of insulin glulisine introduced progressively
           (Arm 3), in type 2 diabetes mellitus patients poorly controlled on basal insulin therapy
           with oral antidiabetic drugs.

      Secondary objectives :

        -  To compare between the 3 treatment groups: evolution of HbA1c over time, percentage of
           subjects with HbA1c &lt;= 7% at the end of the study, evolution of blood glucose profiles,
           incidence of hypoglycemia, insulin doses, evolution of body weight and treatment
           satisfaction.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>From the beginning to the end of the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>24-hour blood glucose levels</measure>
    <time_frame>From the beginning to the end of the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>symptomatic hypoglycemia (diurnal and nocturnal)</measure>
    <time_frame>From the beginning to the end of the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severe hypoglycemia (diurnal and nocturnal),</measure>
    <time_frame>From the beginning to the end of the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin doses</measure>
    <time_frame>From the beginning to the end of the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>From the beginning to the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>From the beginning to the end of the study</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">811</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin Glargine + 3 bolus of Insulin Glulisine + Metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin Glargine + 1 to 3 bolus of Insulin Glulisine + Metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin Glargine + 1 to 3 bolus of Insulin Glulisine + Metformin + Insulin secretagogue</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine</intervention_name>
    <description>One daily injection in the evening. 100 U/ml</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glulisine</intervention_name>
    <description>Given immediately before each of the three main meals. 100 U/ml</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>At same dosages as the previous treatment</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin secretagogue</intervention_name>
    <description>sulfonylurea or glinide</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Type 2 diabetic

          -  BMI ≤ 40 kg/m²

          -  HbA1c &gt; 7%

          -  Treated with basal insulin (NPH, Insulin Zinc, insulin glargine or insulin detemir),
             and at least, two OAD including an insulin secretagogue (sulfonylurea or glinide, at
             any dosage) and metformin (at the maximum tolerated dosage), for more than 6 months

        Exclusion criteria:

          -  Type 1 diabetes mellitus

          -  Treatment with OADs only

          -  Treatment with thiazolidinediones

          -  Treatment with an insulin other than basal insulin (Premix, rapid insulin, fast-acting
             insulin analogue)

          -  Active proliferative diabetic retinopathy, as defined by the application of
             photocoagulation or surgery, in the 6 months before study entry or any other unstable
             (rapidly progressing) retinopathy that may require photocoagulation or surgery during
             the study (confirmed by an optic fundus performed in the 2 years prior study entry)

          -  Pregnancy (women of childbearing potential must have a negative pregnancy test at
             study entry and effective contraception)

          -  Breast-feeding

          -  History of hypersensitivity to the study drug or to drugs with a similar chemical
             structure or to insulin glargine

          -  Treatment with systemic corticosteroids, irrespective of the dose of administration
             and irrespective of the prior or foreseeable treatment duration

          -  Treatment with any investigational product in the last 2 months before study entry,
             except for insulin glargine

          -  Likelihood of requiring treatment during the study period with drugs not permitted by
             the clinical study protocol

          -  Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major
             disease making implementation of the protocol or interpretation of the study results
             difficult

          -  Impaired hepatic function as shown by ALT and/or AST greater than three times the
             upper limit of normal at study entry

          -  Impaired renal function as shown by serum creatinine &gt;135 μmol/l in men and &gt; 110
             μmol/l in women at study entry

          -  History of drug or alcohol abuse

          -  Mental condition rendering the subject unable to understand the nature, scope and
             possible consequences of the study

          -  Subject unlikely to comply with protocol, e.g., uncooperative attitude, inability to
             return for follow-up visits, and unlikelihood of completing the study

          -  Subject deprived of freedom by a judicial or administrative decision

          -  Subject is the investigator or any subinvestigator, research assistant, pharmacist,
             study coordinator, other staff or relative thereof directly involved in the conduct of
             the protocol.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valérie Pilorget, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Gouda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Guildford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>September 14, 2009</last_update_submitted>
  <last_update_submitted_qc>September 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin glulisine</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

